GILD · 10-Q · 2026Q2 · Full report

Competition and Market Share Pressure

GILEAD SCIENCES, INC. · 2026-08-06 · Importance 56 · Surprise 58

Cell Therapy product sales declined 14% in the second quarter and 13% for the first six months of 2026. Gilead attributed the decline primarily to lower demand reflecting ongoing competitive headwinds, indicating pressure in the commercial cell-therapy market. The company also discontinued the Phase 3 EVOKE-03 study of Trodelvy plus Keytruda in first-line metastatic NSCLC after an external Data Monitoring Committee review of progression-free and interim overall-survival data. Gilead recorded no future cash flows for the related NSCLC in-process research and development asset following the discontinuation.